Integrated OTC Stock Analysis

INBP -  USA Stock  

USD 1.09  0.03  2.83%

The recent indifference towards the small price fluctuations of Integrated Biopharma may raise some interest from insiders. The stock closed today at a share price of 1.09 on 100.00 in trading volume. The company executives did not add any value to Integrated Biopharma investors in September. However, most investors can still diversify their portfolios with Integrated Biopharma to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.21. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Integrated Biopharma partners.
Please see Risk vs Return Analysis.

Integrated O TC Stock Analysis 

The Integrated Biopharma otc stock analysis report makes it easy to digest most publicly released information about Integrated Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Integrated OTC Stock analysis module also helps to analyze the Integrated Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Integrated OTC Stock Analysis Notes

About 68.0% of the company shares are held by company insiders. The book value of Integrated Biopharma was currently reported as 0.33. The company had not issued any dividends in recent years. Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.The quote for Integrated Biopharma is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Integrated Biopharma call Gerald Kay at 888 319 6962 or check out

Integrated Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Integrated Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Integrated Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Integrated Biopharma has some characteristics of a very speculative penny stock
Integrated Biopharma has very high historical volatility over the last 90 days
Integrated Biopharma has a frail financial position based on the latest SEC disclosures
About 68.0% of the company shares are held by company insiders
Latest headline from Ascendis Pharma AS Announces US Commercial Launch of SKYTROFA , the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency -

Integrated Biopharma Upcoming and Recent Events

Earnings reports are used by Integrated Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Integrated Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of November 2021
Next Fiscal Quarter End30th of September 2021

Integrated Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Integrated Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Integrated Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Integrated Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of September 2021
Results of Operations and Financial Condition
7th of July 2021
Termination of a Material Definitive Agreement
13th of May 2021
Results of Operations and Financial Condition
8th of April 2021
Other Events
12th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
22nd of January 2021
Other Events

Integrated Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 32.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Integrated Biopharma's market, we take the total number of its shares issued and multiply it by Integrated Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Integrated Profitablity

Integrated Biopharma's profitability indicators refer to fundamental financial ratios that showcase Integrated Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Integrated Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Integrated Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Integrated Biopharma's profitability requires more research than a typical breakdown of Integrated Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 9.01 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 8.48 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.08.
Last ReportedProjected for 2021
Return on Average Assets 0.32  0.26 
Return on Average Equity 0.81  0.72 
Return on Invested Capital 0.37  0.31 
Return on Sales 0.12  0.1 

Management Efficiency

The entity has return on total asset (ROA) of 13.6 % which means that it generated profit of $13.6 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 77.84 %, meaning that it created $77.84 on every $100 dollars invested by stockholders. Integrated Biopharma management efficiency ratios could be used to measure how well integrated biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 20th of October 2021, Return on Average Assets is likely to drop to 0.26. In addition to that, Return on Average Equity is likely to drop to 0.72. As of 20th of October 2021, Total Liabilities is likely to grow to about 13.7 M. Also, Current Liabilities is likely to grow to about 10 M
Last ReportedProjected for 2021
Book Value per Share 0.48  0.52 
Enterprise Value over EBIT 5.00  5.51 
Enterprise Value over EBITDA 4.90  5.06 
Price to Book Value 2.29  1.83 
Tangible Assets Book Value per Share 0.86  0.86 
Enterprise Value40.8 M34.3 M
Tangible Asset Value25.4 M23.5 M

Technical Drivers

As of the 20th of October, Integrated Biopharma retains the Risk Adjusted Performance of 0.0222, market risk adjusted performance of (0.23), and Downside Deviation of 3.0. Integrated Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed nineteen technical drivers for Integrated Biopharma, which can be compared to its competitors. Please check out Integrated Biopharma information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Integrated Biopharma is priced fairly, providing market reflects its last-minute price of 1.09 per share. Given that Integrated Biopharma is a hitting penny stock territory we urge to closely look at its total risk alpha.

Integrated Biopharma Price Movement Analysis

The output start index for this execution was five with a total number of output elements of fifty-six. The Kaufman Adaptive Moving Average allows the user to define Integrated Biopharma range across which they want the smoothing. View also all equity analysis or get more info about kaufman adaptive moving average overlap studies indicator.

Integrated Biopharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integrated Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integrated Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Integrated Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Integrated Biopharma Predictive Daily Indicators

Integrated Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Integrated Biopharma otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Integrated Biopharma Forecast Models

Integrated Biopharma time-series forecasting models is one of many Integrated Biopharma's otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Integrated Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Integrated OTC Stock Analysis

OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Integrated Biopharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Integrated shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Integrated Biopharma. By using and applying Integrated OTC Stock analysis, traders can create a robust methodology for identifying Integrated entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin 0.13  0.11 
Gross Margin 0.15  0.15 
Profit Margin 0.13  0.13 
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Integrated Biopharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.